retatrutide triple agonist clinical trials Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide hits 28.3% weight loss

Saltelli, A., Chan, K

Higher levels of the amino acid homocysteine may be associated with a higher risk of heart attack and stroke

Aronnes clinical trial for orforglipron, the rate of adverse events (meaning health issues that happened during the trial, including things likely not related to the drug itself) appeared to be slightly lower than whats seen with injectables

Many injuries heal but leave behind tissue that functions poorly

Often irritation appears as a symptom of that damage, although this may occur at a sub-clinical level

This helps ensure safety, quality, and consistency for those relying on these drugs for diabetes management or weight loss